Literature DB >> 27296822

Overweight is a predictor of long-term survival in hospitalised patients with exacerbations of COPD.

Paul Stoll1, Saskia Foerster1, J Christian Virchow1, Marek Lommatzsch2.   

Abstract

BACKGROUND: Although hospitalisations due to an exacerbation of chronic obstructive pulmonary disease (COPD) are associated with increased risk of mortality, there is little information on long-term survival after severe COPD exacerbations.
METHODS: The 5-year and 8-year overall survival after hospitalisation due to a COPD exacerbation was explored. In addition, potential predictors of survival were analysed.
RESULTS: The 57 patients with COPD included in this analysis had a median age of 70 years, a median smoking history of 30 pack years and a median forced expiratory volume in the first second (FEV1) of 41.6% predicted at the time of COPD exacerbation. The majority of the patients had either normal weight (body mass index, BMI 18.5-24.99 kg/m(2): 42%) or overweight (BMI ≥ 25 kg/m(2): 54%). The 5-year overall survival after exacerbation was 54%, the 8-year overall survival 42%. The presence of cardiac comorbidities, a FEV1 <50% predicted, an age >70 years and a BMI <25 kg/m(2), but not smoking history or current smoking, were associated with decreased overall survival. Multivariate regression analysis revealed that only BMI, age and FEV1 were independent predictors of long-term survival. Overweight patients (BMI ≥ 25 kg/m(2)) had a substantially higher 5-year overall survival (74%) than patients with a BMI < 25 kg/m(2) (31%).
CONCLUSION: Nearly half of the patients hospitalised due to an exacerbation of COPD die within 5 years after the event. Overweight is a positive predictor of long-term survival in these patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPD; Exacerbations; Mortality; Survival

Mesh:

Year:  2016        PMID: 27296822     DOI: 10.1016/j.rmed.2016.05.016

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Impaired regenerative capacity contributes to skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Ariel Jaitovich
Journal:  Am J Physiol Cell Physiol       Date:  2022-08-22       Impact factor: 5.282

3.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

4.  Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research.

Authors:  Zhenchao Wu; Dong Yang; Zhengwei Ge; Mengdie Yan; Nan Wu; Yi Liu
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

5.  Development of a nomogram for predicting in-hospital mortality of patients with exacerbation of chronic obstructive pulmonary disease.

Authors:  Yukiyo Sakamoto; Yasuhiro Yamauchi; Hideo Yasunaga; Hideyuki Takeshima; Wakae Hasegawa; Taisuke Jo; Yusuke Sasabuchi; Hiroki Matsui; Kiyohide Fushimi; Takahide Nagase
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-05-29

6.  Differences in the Outcome of Patients with COPD according to Body Mass Index.

Authors:  Zichen Ji; Javier de Miguel-Díez; Christian Reynaldo Castro-Riera; José María Bellón-Cano; Virginia Gallo-González; Walther Iván Girón-Matute; Rodrigo Jiménez-García; Ana López-de Andrés; Virginia Moya-Álvarez; Luis Puente-Maestu; Julio Hernández-Vázquez
Journal:  J Clin Med       Date:  2020-03-05       Impact factor: 4.241

Review 7.  Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.